ES2182890T3 - Sintesis de acidos 4-arilo-2-hidroxitetronicos opticamente puros. - Google Patents

Sintesis de acidos 4-arilo-2-hidroxitetronicos opticamente puros.

Info

Publication number
ES2182890T3
ES2182890T3 ES95911075T ES95911075T ES2182890T3 ES 2182890 T3 ES2182890 T3 ES 2182890T3 ES 95911075 T ES95911075 T ES 95911075T ES 95911075 T ES95911075 T ES 95911075T ES 2182890 T3 ES2182890 T3 ES 2182890T3
Authority
ES
Spain
Prior art keywords
optically pure
hydroxythetronic
synthesis
acids
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95911075T
Other languages
English (en)
Inventor
Allen T Hopper
Donald T Witiak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/201,775 external-priority patent/US5399721A/en
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of ES2182890T3 publication Critical patent/ES2182890T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA LA SINTESIS DE ACIDOS 4-ARIL-2-HIDROXITETRONICOS, LABILES ESTEREOGENICAMENTE OPTICAMENTE PUROS DE UN ALDEHIDO OPTICAMENTE PURO. LA INVENCION ADEMAS SE REFIERE AL USO DE TALES COMPUESTOS OPTICAMENTE PUROS COMO POTENTES INHIBIDORES DE AGREGACION DE PLAQUETAS TRABAJANDO AL NIVEL DE LA CICLOOXIGENASA, Y ADICIONALMENTE COMO INHIBIDORES DE CICLOOXIGENASA Y 5-LIPOXIGENASA. LA INVENCION ADEMAS SE REFIERE AL USO FARMACEUTICO DE TALES COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES ARTERIALES CORONARIAS, ESPECIALMENTE EN EL TRATAMIENTO Y/O PREVENCION DE ATEROSCLEROSIS, Y EN EL TRATAMIENTO DE DIVERSAS PATOLOGIAS INFLAMATORIAS, ESPECIALMENTE ARTRITIS.
ES95911075T 1994-02-25 1995-02-22 Sintesis de acidos 4-arilo-2-hidroxitetronicos opticamente puros. Expired - Lifetime ES2182890T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/201,775 US5399721A (en) 1990-01-12 1994-02-25 Synthesis of optically pure 4-aryl-2-hydroxytetronic acids
US08/350,205 US5504108A (en) 1990-01-12 1994-12-05 Optically pure 4-aryl-2-hydroxytetronic acids

Publications (1)

Publication Number Publication Date
ES2182890T3 true ES2182890T3 (es) 2003-03-16

Family

ID=26897085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95911075T Expired - Lifetime ES2182890T3 (es) 1994-02-25 1995-02-22 Sintesis de acidos 4-arilo-2-hidroxitetronicos opticamente puros.

Country Status (10)

Country Link
US (1) US5504108A (es)
EP (1) EP0746551B1 (es)
JP (1) JP3241735B2 (es)
AT (1) ATE223395T1 (es)
CA (1) CA2184068A1 (es)
DE (1) DE69528044T2 (es)
DK (1) DK0746551T3 (es)
ES (1) ES2182890T3 (es)
PT (1) PT746551E (es)
WO (1) WO1995023139A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
AU1676300A (en) * 1999-12-29 2001-07-16 Oxis Isle Of Man, Limited Methods for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones
HUP0302068A3 (en) 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
WO2003045888A1 (en) * 2001-11-30 2003-06-05 Nippon Shokubai Co., Ltd. Optically active mandelic acid and its derivative, and method for crystallization thereof
KR20100134082A (ko) * 2001-12-21 2010-12-22 오르토-맥네일 파마슈티칼, 인코퍼레이티드 2-(치환된 페닐)-2-하이드록시-에틸 카바메이트의 제조방법
WO2003053916A1 (en) * 2001-12-21 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. Process for preparing 2-(substituted phenyl) - 2 - hydroxy-ethyl carbamates
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
GB2512863A (en) * 2013-04-09 2014-10-15 Pornthip Lattmann Medicinal applications of arylated hydroxy-tetronic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2830268B2 (ja) * 1989-01-21 1998-12-02 武田薬品工業株式会社 アスコルビン酸誘導体の製造法
US5095126A (en) * 1990-01-12 1992-03-10 Ohio State University Research Foundation Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids
US5071872A (en) * 1990-08-14 1991-12-10 The Ohio State University Research Foundation Method for improving interleukin-2 activity using aci-reductone compounds

Also Published As

Publication number Publication date
EP0746551B1 (en) 2002-09-04
ATE223395T1 (de) 2002-09-15
CA2184068A1 (en) 1995-08-31
WO1995023139A1 (en) 1995-08-31
JP3241735B2 (ja) 2001-12-25
DK0746551T3 (da) 2003-01-06
DE69528044D1 (de) 2002-10-10
EP0746551A1 (en) 1996-12-11
JPH10500663A (ja) 1998-01-20
US5504108A (en) 1996-04-02
PT746551E (pt) 2003-01-31
DE69528044T2 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
ATE253586T1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivat
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
MX9307779A (es) Compuestos benzoicos fundidos.
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
DE60233420D1 (de) Fumagillolderivate und verfahren zu deren herstellung
AU8490901A (en) Urea compounds and methods of uses
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
IL190905A0 (en) 4-alkoxy cyclohexane-1-amino carboxylic acids and processes for their prepatation
PT1039895E (pt) Utilizacao de acidos 3-benzoilfenilaceticos respectivos esteres ou amidas para o tratamento do glaucoma glc1a
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2119300T3 (es) Procedimiento para la preparacion de 5-formilvalerato.
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
DE50312948D1 (de) Alicyclische ester mit moschusgeruch
ES2182890T3 (es) Sintesis de acidos 4-arilo-2-hidroxitetronicos opticamente puros.
SE9601677D0 (sv) New use
SE9801494D0 (sv) Novel use
ES2190471T3 (es) Procedimiento para producir derivados de guanidina, intermedios de dichos compuestos y su produccion.